DE60031285T2
(de)
|
1999-08-27 |
2007-08-30 |
Chemocentryx Inc., Mountain View |
Heterozyclische verbindungen und verfahren zur modulierung von cxcr3 funktion
|
US20070021493A1
(en)
|
1999-09-16 |
2007-01-25 |
Curis, Inc. |
Mediators of hedgehog signaling pathways, compositions and uses related thereto
|
US7671200B2
(en)
|
1999-10-27 |
2010-03-02 |
Cytokinetics, Inc. |
Quinazolinone KSP inhibitors
|
US7230000B1
(en)
|
1999-10-27 |
2007-06-12 |
Cytokinetics, Incorporated |
Methods and compositions utilizing quinazolinones
|
US6545004B1
(en)
*
|
1999-10-27 |
2003-04-08 |
Cytokinetics, Inc. |
Methods and compositions utilizing quinazolinones
|
US7115653B2
(en)
|
2000-03-30 |
2006-10-03 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
US8852937B2
(en)
|
2000-03-30 |
2014-10-07 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
EP1343505A1
(de)
*
|
2000-12-11 |
2003-09-17 |
Tularik Inc. |
Cxcr3 antagoniste
|
US6992082B2
(en)
|
2001-01-19 |
2006-01-31 |
Cytokinetics, Inc. |
Phenothiazine kinesin inhibitors
|
US6809102B2
(en)
|
2001-03-29 |
2004-10-26 |
Bristol-Myers Squibb Company |
Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
|
US6900214B2
(en)
|
2001-03-29 |
2005-05-31 |
Bristol-Myers Squibb Company |
Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
|
US6794379B2
(en)
|
2001-06-06 |
2004-09-21 |
Tularik Inc. |
CXCR3 antagonists
|
MXPA03011933A
(es)
|
2001-06-22 |
2004-03-26 |
Pfizer Prod Inc |
Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados.
|
DE60236605D1
(de)
*
|
2001-09-05 |
2010-07-15 |
Minerva Biotechnologies Corp |
Zusammensetzungen und deren verwendung zur behandlung von krebs
|
JP2005511581A
(ja)
|
2001-11-07 |
2005-04-28 |
メルク エンド カムパニー インコーポレーテッド |
有糸分裂キネシン阻害剤
|
WO2003043961A2
(en)
*
|
2001-11-19 |
2003-05-30 |
Iconix Pharmaceuticals, Inc. |
Modulators of rho c activity
|
AU2002346471A1
(en)
*
|
2001-11-20 |
2003-06-10 |
Cytokinetics, Inc. |
Process for the racemization of chiral quinazolinones
|
DE60231439D1
(de)
|
2001-12-06 |
2009-04-16 |
Merck & Co Inc |
Mitotische kinesinhemmer
|
EP1465896A4
(de)
|
2001-12-06 |
2006-01-11 |
Merck & Co Inc |
Inhibitoren von mitotischem kinesin
|
CA2467722A1
(en)
|
2001-12-06 |
2003-06-19 |
Merck & Co., Inc. |
Thienopyrimidinone derivatives as mitotic kinesin inhibitors
|
DE60232994D1
(de)
*
|
2001-12-06 |
2009-08-27 |
Merck & Co Inc |
Inhibitoren von mitotischem kinesin
|
AU2002351183B2
(en)
|
2001-12-06 |
2008-05-08 |
Merck Sharp & Dohme Corp. |
Mitotic kinesin inhibitors
|
KR100915287B1
(ko)
|
2001-12-11 |
2009-09-03 |
교와 핫꼬 기린 가부시키가이샤 |
티아디아졸린 유도체
|
US7166595B2
(en)
*
|
2002-05-09 |
2007-01-23 |
Cytokinetics, Inc. |
Compounds, methods and compositions
|
DE60312516T2
(de)
*
|
2002-06-14 |
2007-11-22 |
Merck & Co., Inc. |
Inhibitoren von mitotischem kinesin
|
DE60326248D1
(de)
*
|
2002-07-17 |
2009-04-02 |
Cytokinetics Inc |
Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
|
AU2003299612A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Cytokinetics |
Compounds, compositions and methods
|
CN1894234A
(zh)
*
|
2003-03-25 |
2007-01-10 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
WO2004092123A2
(en)
*
|
2003-04-10 |
2004-10-28 |
Microbia, Inc. |
Inhibitors of fungal invasion
|
AU2004230799B2
(en)
|
2003-04-18 |
2010-03-18 |
Fujifilm Corporation |
Mitotic kinesin inhibitor
|
AU2004249730A1
(en)
|
2003-06-20 |
2004-12-29 |
Novartis Vaccines And Diagnostics, Inc. |
Pyridino(1,2-A)pyrimidin-4-one compounds as anticancer agents
|
US7666862B2
(en)
*
|
2003-08-15 |
2010-02-23 |
Merck & Co., Inc. |
Mitotic Kinesin Inhibitors
|
DK1689724T3
(da)
*
|
2003-11-25 |
2012-02-27 |
Novartis Ag |
Quinazolinonforbindelser som anticancermidler
|
EP1692112A4
(de)
*
|
2003-12-08 |
2008-09-24 |
Cytokinetics Inc |
Verbindungen, zusammensetzungen und verfahren
|
US7662581B1
(en)
|
2003-12-18 |
2010-02-16 |
Novartis Vaccines And Diagnostics, Inc. |
Eg5 co-crystals
|
JP2007518711A
(ja)
|
2003-12-19 |
2007-07-12 |
メルク エンド カムパニー インコーポレーテッド |
有糸分裂キネシン阻害剤
|
JPWO2005061707A1
(ja)
*
|
2003-12-24 |
2007-07-12 |
協和醗酵工業株式会社 |
癌細胞のEg5阻害剤に対する感受性を判定する方法
|
JP2007530545A
(ja)
*
|
2004-03-22 |
2007-11-01 |
メルク エンド カムパニー インコーポレーテッド |
有糸分裂キネシン阻害剤
|
DK1737831T3
(da)
|
2004-04-02 |
2013-08-19 |
Prana Biotechnology Ltd |
Neurologisk aktive forbindelser
|
DK1761540T3
(en)
*
|
2004-05-13 |
2016-11-21 |
Icos Corp |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase DELTA
|
RU2385867C2
(ru)
|
2004-05-21 |
2010-04-10 |
Новартис Аг |
Замещенные производные хинолина как ингибиторы митотического кинезина
|
EP1755609A1
(de)
*
|
2004-05-25 |
2007-02-28 |
Icos Corporation |
Verfahren zur behandlung und/oder prävention von überschiessender proliferation von hämatopoetischen zellen
|
MXPA06014909A
(es)
|
2004-06-18 |
2007-02-28 |
Chiron Corp |
Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
|
US7375102B2
(en)
|
2004-06-28 |
2008-05-20 |
Amgen Sf, Llc |
Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
|
US7271271B2
(en)
|
2004-06-28 |
2007-09-18 |
Amgen Sf, Llc |
Imidazolo-related compounds, compositions and methods for their use
|
US7939538B2
(en)
|
2004-06-28 |
2011-05-10 |
Amgen Inc. |
Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
|
UY29070A1
(es)
|
2004-08-18 |
2006-03-31 |
Astrazeneca Ab |
Enantiómeros de heterocíclicos fusionados y sus usos
|
CA2584412C
(en)
*
|
2004-09-14 |
2017-05-09 |
Minerva Biotechnologies Corporation |
Methods for diagnosis and treatment of cancer
|
MX2007004699A
(es)
|
2004-10-19 |
2007-06-14 |
Novartis Vaccines & Diagnostic |
Derivados de indol y bencimidazol.
|
US20080102068A1
(en)
*
|
2005-01-19 |
2008-05-01 |
Coleman Paul J |
Mitotic Kinesin Inhibitors
|
DE102005011822A1
(de)
*
|
2005-03-15 |
2006-09-21 |
Merck Patent Gmbh |
Phthalazinone
|
EP1908755A4
(de)
|
2005-06-24 |
2009-06-24 |
Kyowa Hakko Kirin Co Ltd |
Therapeutisches mittel gegen restenose
|
MY147188A
(en)
*
|
2005-08-09 |
2012-11-14 |
Novartis Ag |
Substituted imidazole compounds as ksp inhibitors
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
EP2073807A1
(de)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmazeutische kombinationen
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
WO2008057468A1
(en)
|
2006-11-02 |
2008-05-15 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
US8129358B2
(en)
|
2006-11-13 |
2012-03-06 |
Novartis Ag |
Substituted pyrazole and triazole compounds as KSP inhibitors
|
CN101622247A
(zh)
|
2007-01-05 |
2010-01-06 |
诺瓦提斯公司 |
作为驱动蛋白纺锤体蛋白抑制剂的咪唑衍生物
|
BRPI0806245B1
(pt)
|
2007-01-10 |
2022-01-25 |
Msd Italia S.R.L. |
Compostos de fórmula i e seus usos
|
BRPI0808523A2
(pt)
|
2007-03-01 |
2014-08-19 |
Novartis Vaccines & Diagnostic |
Inibidores de pim cinase e métodos de seu uso
|
CA2685967A1
(en)
|
2007-05-21 |
2008-11-21 |
Novartis Ag |
Csf-1r inhibitors, compositions, and methods of use
|
MX2009013815A
(es)
|
2007-06-22 |
2010-03-01 |
Arqule Inc |
Compuestos de quinazolinona y metodos de uso para los mismos.
|
EP2170076B1
(de)
|
2007-06-27 |
2016-05-18 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino-derivate als histondeacetylase-hemmer
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
PT2355828T
(pt)
|
2008-11-13 |
2018-07-02 |
Gilead Calistoga Llc |
Terapias para malignidades hematológicas
|
WO2011011550A1
(en)
|
2009-07-21 |
2011-01-27 |
Calistoga Pharmaceuticals Inc. |
Treatment of liver disorders with pi3k inhibitors
|
CA2805265A1
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
WO2012024170A2
(en)
|
2010-08-17 |
2012-02-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
EP2615916B1
(de)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Kondensierte pyrazolderivate als neue erk-hemmer
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
JP2014514321A
(ja)
|
2011-04-21 |
2014-06-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
インスリン様増殖因子1受容体阻害剤
|
KR20140133590A
(ko)
|
2012-03-05 |
2014-11-19 |
길리아드 칼리스토가 엘엘씨 |
(s)-2-(1-(9h-퓨린-6-일아미노)프로필)-5-플루오로-3-페닐퀴나졸린-4(3h)-온의 다형체 형태
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
AU2013364068B2
(en)
|
2012-12-21 |
2016-10-20 |
Gilead Calistoga Llc |
Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
|
EP2935246B1
(de)
|
2012-12-21 |
2018-07-25 |
Gilead Calistoga LLC |
Isochinolinon- oder chinazolinon-phosphatidylinositol-3-kinasehemmer
|
AR096621A1
(es)
|
2013-06-14 |
2016-01-20 |
Gilead Sciences Inc |
Inhibidores de isómeros de la fosfatidilinositol 3-quinasa (pi3k)
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
AU2014364414A1
(en)
|
2013-12-20 |
2016-06-30 |
Gilead Calistoga Llc |
Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
|
NZ736970A
(en)
|
2013-12-20 |
2018-11-30 |
Gilead Calistoga Llc |
Process methods for phosphatidylinositol 3-kinase inhibitors
|
SG11201609527PA
(en)
|
2014-06-13 |
2016-12-29 |
Gilead Sciences Inc |
Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
|
CN106459005A
(zh)
*
|
2014-06-13 |
2017-02-22 |
吉利德科学公司 |
磷脂酰肌醇3‑激酶抑制剂
|
MX2016016528A
(es)
|
2014-06-13 |
2017-03-27 |
Gilead Sciences Inc |
Inhibidores de fosfatidilinositol 3-quinasa.
|
CA2952037A1
(en)
|
2014-06-13 |
2015-12-17 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
US9957267B2
(en)
|
2015-07-01 |
2018-05-01 |
Crinetics Pharmaceuticals, Inc. |
Somatostatin modulators and uses thereof
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
WO2019023278A1
(en)
|
2017-07-25 |
2019-01-31 |
Crinetics Pharmaceuticals, Inc. |
MODULATORS OF SOMATOSTATIN AND USES THEREOF
|
CN111189935A
(zh)
*
|
2019-12-30 |
2020-05-22 |
卓和药业集团有限公司 |
盐酸右美托咪定的高效液相色谱分析方法
|